Transforming the lives of the ageing global population

Our mission is to develop breakthrough treatments for three major reasons which deprive older people of their health, independence and longevity.

The ‘silver tsunami’ or ‘grey wave’ has arrived with the baby boomer generation passing the age of 65 and with it a dramatic increase in the number of people in developed countries living into their 80s and older.

This dramatic shift in population demographics brings with it a dramatic rise in the need for medicines for diseases of ageing.

Concerningly, medicine is remarkably unprepared for this coming tide.

Where once most people didn’t live long enough to suffer advanced dementia, dementia is already the leading cause of death of older women and expected soon to be the major cause of death of older men.

New technologies, new drugs are urgently needed and Filamon believes it is well placed to play a leading role in meeting this need.

The 3 major causes of death > 65 years of age
The 4 major causes of blindness > 65 years of age
Filamon drugs
  • Heart disease
  • Cancer
  • Dementia
  • Macular degeneration
  • Glaucoma
  • Cataract
  • Diabetic retinopathy
Approximate current and predicted values for markets (US$ billion) that Filamon is targeting:
  Current (2023) Predicted (2031)
Dementia* 22 38
Macular degeneration/diabetic retinopathy** 11 18
Cancer n/a >30***